MEDICATION GUIDES · GUIDE 06

Anxiolytics

Anti-anxiety medicines range from fast-acting benzodiazepines to slower daily options and medicines aimed mainly at physical symptoms. Speed, sedation, dependence risk, and the type of anxiety all matter.

These guides describe patterns across a drug class, not a prediction for one person. Benefits, side effects, interactions, and tapering needs vary by medication, dose, health history, and other treatments. Never start, stop, or change a psychiatric medication without the prescribing clinician.

EVIDENCE REVIEW
SEPTEMBER 24, 2026

Benzodiazepines: fast relief, real tradeoffs

Benzodiazepines strengthen GABA, the brain’s main braking signal. They can calm severe anxiety or panic quickly, but the same action can cause sleepiness, slowed thinking, memory gaps, poor coordination, and impaired driving. They are most useful as short-term, targeted tools—for example during acute severe anxiety, alcohol withdrawal, catatonia, or a procedure—while a longer-term plan is built.

Fast does not mean low-risk. Physical dependence can develop after days to weeks of steady use, even when the medicine is taken exactly as prescribed. Dependence is the body adapting to a drug; it is not the same as addiction or misuse.

SOURCE · FDA BENZODIAZEPINE WARNING SOURCE · 2023 AGS BEERS CRITERIA

How common benzodiazepines differ

AlprazolamFast onset and a short half-life of about 11–12 hours. It can relieve acute panic quickly, but between-dose rebound and withdrawal can be intense.

LorazepamFairly fast onset and an intermediate half-life of about 10–20 hours. It has no active metabolites and is cleared more simply than several peers, but it still carries class-wide sedation and dependence risks.

ClonazepamSlower onset and a long half-life of about 18–50 hours. Its longer presence can smooth between-dose changes but can also prolong sedation.

DiazepamFast onset and a very long half-life—about 20–100 hours when active metabolites are included. Its long tail can help supervised tapers, while lingering effects can cause next-day impairment.

ChlordiazepoxideModerately fast onset and a very long half-life of about 24–100 hours or more with active metabolites. Its main modern role is alcohol withdrawal rather than routine anxiety treatment.

Half-life describes how long the body takes to clear half a dose; it does not predict exactly how long one person will feel an effect. Age, liver function, other medicines, dose, and regular use can change the experience.

SOURCE · MEDSCAPE COMPARISON SOURCE · ASAM PHARMACOKINETICS SOURCE · CURRENT PSYCHIATRY

Non-benzodiazepine options

BuspironeA daily serotonin 5-HT1A medicine for chronic anxiety. It is not sedating or dependence-forming, but it usually needs 2–4 weeks to work and is not an as-needed rescue pill.

HydroxyzineA sedating antihistamine that can work in about 30–60 minutes and is not controlled. Drowsiness, dry mouth, dizziness, and next-day grogginess are the main tradeoffs; heart-rhythm risk matters for some people.

PropranololAn off-label beta-blocker for physical performance-anxiety symptoms such as racing heart, tremor, sweating, or shaky voice. It does not directly quiet anxious thoughts and is not first-line for chronic anxiety disorders.

PregabalinCan reduce overactive nerve signaling and has evidence for generalized anxiety. It is approved for GAD in the European Union but not by the FDA in the United States; U.S. anxiety use is off-label. It is Schedule V and has its own sedation, dependence, and withdrawal risks.

For chronic anxiety disorders, CBT and SSRIs or SNRIs are generally the first-line foundation. A non-benzodiazepine option may be chosen because of the symptom pattern, other conditions, or a need to avoid sedation or higher dependence risk.

SOURCE · BUSPIRONE OVERVIEW SOURCE · HYDROXYZINE OVERVIEW SOURCE · PROPRANOLOL OVERVIEW SOURCE · PREGABALIN SAFETY REVIEW

Dependence, withdrawal, and tapering

Never stop a benzodiazepine abruptly after regular use. Sudden stopping can cause rebound anxiety and insomnia, tremor, sweating, nausea, irritability, confusion, psychosis, and seizures. Short-acting medicines such as alprazolam can produce faster, more intense withdrawal; longer-acting medicines may produce later, more prolonged symptoms.

A taper is slow, individualized, and collaborative. Current guidance commonly starts with reductions of about 5–10% at a time and advises that cuts generally not exceed about 25% every two weeks, but symptoms—not a calendar—set the pace. For long-term use, a taper can take months. A prescriber may switch to a longer-acting medicine first, and CBT or CBT-I can support the process.

SOURCE · ASAM TAPER GUIDELINE SUMMARY SOURCE · VA BENZODIAZEPINE GUIDE

Interactions, overdose, and higher-risk situations

Alcohol, opioids, and other sedatives: effects stack. The FDA boxed warning for benzodiazepines plus opioids includes extreme sleepiness, respiratory depression, coma, and death. Do not combine them unless the prescriber has specifically reviewed the combination.
Overdose: if someone is extremely sleepy or cannot be awakened, is breathing slowly or shallowly, or has pale or bluish lips, call 911, stay with the person, and tell responders what was taken. Flumazenil is a hospital-only medicine and can trigger seizures or dangerous rhythms in some overdoses.
Older adults: the 2023 AGS Beers Criteria recommend avoiding benzodiazepines because of delirium, falls, fractures, cognitive impairment, and motor-vehicle crashes.
Breathing problems: sleep apnea, COPD, and other respiratory conditions can increase risk. Tell the prescriber before using a sedative.
Storage: keep controlled medicines locked and out of reach of children and teens. Never share a prescription.

SOURCE · OPIOID–BENZODIAZEPINE WARNING SOURCE · FLUMAZENIL REVIEW SOURCE · 2023 AGS BEERS CRITERIA

Pregnancy, breastfeeding, and what remains uncertain

Benzodiazepines cross the placenta. Later-pregnancy exposure can be associated with low muscle tone, feeding or breathing difficulty, and newborn withdrawal. Evidence about overall birth-defect risk is inconsistent; later and larger studies have not shown a clear significant increase overall. In breastfeeding, longer-acting medicines can accumulate; if treatment is needed, lorazepam or oxazepam may be preferred and the infant should be watched for unusual sleepiness, poor feeding, or limpness.

The long-term controversy deserves honesty: some people remain stable on specialist-supervised prescriptions and can be harmed by a forced, rapid taper, while evidence for routine daily benzodiazepine treatment over months or years is limited and adverse effects may persist. Decisions should be individualized and shared—not abrupt or punitive.

SOURCE · PREGNANCY REVIEW SOURCE · MALFORMATION DATA REVIEW SOURCE · BREASTFEEDING GUIDANCE SOURCE · LONG-TERM USE REVIEW